Poultry mycoplasma antigen, gene thereof and recombinant vectors

Details Poultry mycoplasma antigen, gene thereof and recombinant vectors Poultry mycoplasma antigen, gene thereof and recombinant vectors

1994-01-25

1996-02-06

Mosher, Mary E.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

4241921, 4242641, 530350, 930200, 536 237, 4353201, 4352523, 4352402, 43525231, 43525233, A61K 3902, C07K 1430, C12N 1531, C12N 121

Patent

active

054894301

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to antigen proteins of Mycoplasma gallisepticum infected to poultry;, recombinant vectors integrated with genes encoding to antigen proteins, hosts transformed by the vectors, as well as poultry vaccines for Mycoplasma gallisepticum infections utilizing the antigen proteins.


BACKGROUND

Mycoplasma gallisepticum infectious disease, that is one of the most serious infections on poultry such as chickens, etc., is characterized by chronic respiratory impairment accompanied by inflammation of the air sac in chicken. When chickens were infected with Mycoplasma gallisepticum, an egg-laying rate and a hatching rate of eggs produced by infected chickens are markedly reduced. As the result, shipping of eggs and egg-laying chickens decrease so that a considerable economic loss is caused. In addition, Mycoplasma gallisepticum infection induces the reduction in immunity so that chickens are liable to suffer from other infectious diseases to cause complication of severe infectious diseases. Furthermore, Mycoplasma gallisepticum is known to be a pathogen of sinusitis in turkeys.
The present inventors already found proteins react with antisera against Mycoplasma gallisepticum (Japanese Patent Application Laid-Open No. 2-111795). It is expected that these proteins would be useful as vaccines for preventing Mycoplasma gallisepticum infections, but in order to prepare more potent vaccines, it is desired to provide proteins having a higher activity.


DISCLOSURE OF THE INVENTION

As a result of extensive investigations to obtain more effective vaccines for preventing Mycoplasma gallisepticum infections, the present inventors have selected TMG-1 from the proteins disclosed in Japanese Patent Application Laid-Open No. 2-111795 Supra. It has then be found that addition of protein of about 11 kilodaltons to TMG-1 markedly increased the antigenicity of Mycoplasma gallisepticum, antisera induced using the addition product as antigen prevent the growth of Mycoplasma gallisepticum, and the protein described above can be expected to be useful as poultry vaccine for preventing Mycoplasma gallisepticum infections and also useful as diagnosis of Mycoplasma gallisepticum infections for poultry use. The present invention has thus come to be accomplished.


BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a restriction enzyme cleavage map of DNA fragment which can be used for recombination in the present invention.
FIG. 2 illustratively shows the procedure for cloning TTM-1 DNA to M13 phage.
FIG. 3 illustratively shows the procedure for producing a site-specific mutant prepared using artificially synthesized oligonucleotide primer.
FIG. 4 illustratively shows the procedure for producing plasmid pMTTMIE which expresses protein TTMG-1 encoded by TTM-1'.


BEST MODE FOR PRACTICING THE INVENTION

According to a first aspect of the present invention, there is provided a protein which causes an antigen-antibody reaction with Mycoplasma gallisepticum poultry antisera and has a molecular weight of about 40 kilodaltons (hereinafter abbreviated as kd) encoded by DNA sequence having a restriction enzyme cleavage map shown in FIG. 1. According to a second aspect of the present invention, there is provided a DNA sequence which encodes the amino acid sequence (see SEQ ID NO:1. According to a third aspect of the present invention, there is provided a recombinant vector containing the DNA and a host transformed or transfected by the recombinant vector. According to a fourth aspect of the present invention, there is provided a poultry vaccine for preventing Mycoplasma gallisepticum infections, comprising the said protein as an effective component.
That is, in the first aspect of the present invention, the protein is the one that causes an antigen-antibody reaction with sera immunized or infected with Mycoplasma gallisepticum and has a molecular weight of about 40 Kd encoded by DNA sequence having a restriction enzyme cleavage map shown in FIG. 1. Specific examples include a protein having an amino acid sequenc

REFERENCES:
Inamine, J. M. et al. 1990, J. Bacteriol. vol. 172 pp. 504-506, Colleux, L. et al. 1986--Cell vol. 44 pp. 521-533.
Saito, S. et al. 1993, Vaccine vol. 11 pp. 1061-1066.

Affiliated with

Also associated with

Rating

Poultry mycoplasma antigen, gene thereof and recombinant vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Poultry mycoplasma antigen, gene thereof and recombinant vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Poultry mycoplasma antigen, gene thereof and recombinant vectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2173928